T1	PROC 46 66	Estudio de extensión
T2	CHEM 70 81	secukinumab
#1	AnnotatorNotes T2	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	DISO 110 137	artritis idiopática juvenil
#2	AnnotatorNotes T3	C3495559; Juvenile arthritis; Disease or Syndrome
T4	DISO 140 174	artritis relacionada con entesitis
#3	AnnotatorNotes T4	C3495919; Enthesitis-Related Arthritis; Disease or Syndrome
T5	PROC 198 218	Estudio de extensión
T6	PROC 1016 1036	estudio de extensión
T7	CHEM 222 233	secukinumab
#4	AnnotatorNotes T7	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	PROC 250 296	evaluar la eficacia, seguridad y tolerabilidad
T9	DISO 371 398	artritis idiopática juvenil
#5	AnnotatorNotes T9	C3495559; Juvenile arthritis; Disease or Syndrome
T10	DISO 400 427	artritis psoriásica juvenil
#6	AnnotatorNotes T10	C3714758; Juvenile psoriatic arthritis; Disease or Syndrome
T12	DISO 430 464	artritis relacionada con entesitis
#8	AnnotatorNotes T12	C3495919; Enthesitis-Related Arthritis; Disease or Syndrome
T15	DISO 489 523	Artritis relacionada con entesitis
#11	AnnotatorNotes T15	C3495919; Enthesitis-Related Arthritis; Disease or Syndrome
T16	DISO 526 553	Artritis psoriásica juvenil
#12	AnnotatorNotes T16	C3714758; Juvenile psoriatic arthritis; Disease or Syndrome
T17	PROC 702 713	tratamiento
#13	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	PROC 823 843	tratamiento continuo
T19	CHEM 848 859	secukinumab
#14	AnnotatorNotes T19	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T20	PROC 908 917	protocolo
#15	AnnotatorNotes T20	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T21	CHEM 1075 1112	fármacos inmunomoduladores biológicos
T22	CHEM 1135 1146	secukinumab
#16	AnnotatorNotes T22	C3179547; secukinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T23	PROC 1207 1218	tratamiento
#17	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	DISO 1290 1298	síntomas
#18	AnnotatorNotes T24	C1457887; Symptoms; Sign or Symptom
T25	PROC 1348 1357	protocolo
#19	AnnotatorNotes T25	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T26	PROC 961 975	administración
#20	AnnotatorNotes T26	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T27	CHEM 979 992	vacunas vivas
#21	AnnotatorNotes T27	C0042211; live vaccine; Immunologic Factor · Pharmacologic Substance
T28	Date 13 17	2018
T29	Route 82 92	subcutáneo
T30	LIVB 96 105	pacientes
#22	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	Route 234 244	subcutáneo
T32	Date 297 310	a largo plazo
T33	Duration 331 337	4 años
T34	LIVB 341 350	pacientes
#23	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T35	LIVB 587 596	pacientes
#24	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	LIVB 770 782	investigador
#25	AnnotatorNotes T36	C0035173; Research Personnel; Professional or Occupational Group
T37	LIVB 788 797	pacientes
#26	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T39	LIVB 1051 1059	paciente
#27	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T41	LIVB 1161 1169	paciente
#28	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T38	Date 720 733	la semana 104
T40	Neg_cue 1127 1134	excepto
A1	Assertion T22 Negated
#29	AnnotatorNotes T29	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
#30	AnnotatorNotes T31	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
#31	AnnotatorNotes T8	C0511730; Identify product efficacy and safety issues; Health Care Activity + C3274448; Tolerability Study; Research Activity 
R1	Has_Route_or_Mode Arg1:T2 Arg2:T29	
R2	Experiences Arg1:T30 Arg2:T2	
R3	Experiences Arg1:T30 Arg2:T3	
R4	Experiences Arg1:T30 Arg2:T4	
R6	Has_Route_or_Mode Arg1:T7 Arg2:T31	
R9	Experiences Arg1:T34 Arg2:T7	
R10	Experiences Arg1:T34 Arg2:T9	
R11	Experiences Arg1:T34 Arg2:T10	
R12	Experiences Arg1:T34 Arg2:T12	
R14	Before Arg1:T17 Arg2:T38	
T42	Observation 672 713	completado todo el periodo de tratamiento
#32	AnnotatorNotes T42	C0580352; Treatment completed; Finding
R15	Experiences Arg1:T35 Arg2:T42	
R16	Experiences Arg1:T35 Arg2:T17	
R17	Experiences Arg1:T37 Arg2:T18	
R18	Used_for Arg1:T19 Arg2:T18	
R19	Used_for Arg1:T27 Arg2:T26	
R20	Overlap Arg1:T26 Arg2:T6	
R21	Negation Arg1:T40 Arg2:T22	
R22	Experiences Arg1:T39 Arg2:T21	
R23	Experiences Arg1:T39 Arg2:T22	
R24	Experiences Arg1:T41 Arg2:T23	
T43	Neg_cue 1247 1255	falta de
T44	Observation 1256 1263	mejoría
A2	Assertion T44 Negated
#33	AnnotatorNotes T44	C0184511; Improved; Finding (?)
R25	Negation Arg1:T43 Arg2:T44	
R26	Experiences Arg1:T41 Arg2:T44	
T45	Observation 1269 1282	empeoramiento
#34	AnnotatorNotes T45	C1457868; Worse; Finding
R27	Experiences Arg1:T41 Arg2:T45	
T46	Neg_cue 1174 1176	no
T47	Observation 1192 1218	beneficios del tratamiento
A3	Assertion T47 Negated
R28	Negation Arg1:T46 Arg2:T47	
T48	Quantifier_or_Qualifier 1113 1126	concomitantes
#36	AnnotatorNotes T48	C0521115; Simultaneous; Temporal Concept
R30	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T48	
R31	Experiences Arg1:T41 Arg2:T24	
T49	CONC 948 957	Previsión
#37	AnnotatorNotes T49	C1301732; Planned; Functional Concept
R5	Has_Duration_or_Interval Arg1:T7 Arg2:T33	
R8	Overlap Arg1:T7 Arg2:T32	
#7	AnnotatorNotes T47	C0557186; Benefit status; Finding (?)
R7	Experiences Arg1:T41 Arg2:T47	
R13	Before Arg1:T24 Arg2:T45	
#9	AnnotatorNotes T32	C0443252; Long-term; Temporal Concept
A4	Experiencer T30 Patient
A5	Experiencer T34 Patient
A6	Experiencer T35 Patient
A7	Experiencer T36 Other
A8	Experiencer T37 Patient
A9	Status T26 Future
A10	Status T27 Future
A11	Experiencer T39 Patient
A12	Experiencer T41 Patient
A13	Status T47 Future
